Company Growth (employees)
AstraZeneca was founded in 1999 and is headquartered in Cambridge, GB
Key People at AstraZeneca
Pascal Soriot
Executive Director and Chief Executive Officer
Marc Dunoyer
CFO
Herren Wu
CTO
Bahija Jallal
Executive Vice President
Menelas Pangalos
Executive Vice President
Mark Mallon
Executive Vice President
Jeff Pott
General Counsel
Katarina Ageborg
Chief Compliance Officer
Caroline Hempstead
Executive Vice President, Human Resources and Corporate Affairs (interim)
Pam Cheng
Executive Vice-President
Fiona Cicconi
Executive Vice-President, Human Resources
AstraZeneca Office Locations
AstraZeneca has offices in Cambridge, London, Bangalore, Hong Kong and in 166 other locations
Wedel, DE
Wedel, Tinsdaler Weg 183
Wilmington, US
1800 Concord Pike, P.O. Box 15437
Osaka, JP
Grand Front Osaka Tower B, 3-1, Ofuka-cho, Kita-ku
Shanghai, CN
43/F CITIC Square, 1168 Nan Jing Xi Road
Hong Kong, HK
18/F, Shui On Centre, 6-8 Harbour Road, Wanchai
Bangalore, IN
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road
AstraZeneca Data and Metrics
AstraZeneca Financial Metrics
AstraZeneca's revenue was reported to be $21.3 b in FY, 2016 which is a 10% decrease from the previous period.
USD
Revenue (FY, 2016) | 21.3 b |
Revenue growth (FY, 2015 - FY, 2016), % | (10%) |
Gross profit (FY, 2016) | 17.2 b |
Gross profit margin (FY, 2016), % | 81% |
Net income (FY, 2016) | 3.4 b |
Market capitalization (22-Sep-2017) | 86 b |
Closing share price (22-Sep-2017) | 32.8 |
Cash (31-Dec-2016) | 3.9 b |
AstraZeneca's current market capitalization is $86 b.
- Source: Company Filings
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 25.7 b | 26.1 b | 23.6 b | 21.3 b |
Revenue growth, % | 1% | (9%) | (10%) | |
Cost of goods sold | 5.3 b | 5.8 b | 4.6 b | 4.1 b |
Gross profit | 20.5 b | 20.3 b | 19 b | 17.2 b |
- Source: Company Filings
| GBP | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 6.1 b | 4.7 b | 4.6 b | 3.9 b |
Accounts Receivable | 3.6 b | 3.5 b | 3.4 b | 2 b |
Current Assets | 13.2 b | 12.2 b | 11.7 b | 10.1 b |
PP&E | 6.4 b | 7 b | 7.2 b | 8 b |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash From Operating Activities | 7.4 b | 7.1 b | 3.3 b | 4.1 b |
Cash From Financing Activities | (2 b) | (2 b) | 649.3 m | 1.7 b |
Income Taxes Paid | (457.7 m) | (8.1 m) | (179.7 m) | (113.1 m) |
| Y, 2016 | |
|---|---|
Financial Leverage | 4.2 x |
AstraZeneca Market Value History
AstraZeneca Revenue Breakdown
AstraZeneca Median Salaries
Source: 105 public H-1B filings from AstraZeneca
Market Position of AstraZeneca
Traffic Overview of AstraZeneca
AstraZeneca Online and Social Media Presence
AstraZeneca News and Updates
September 22, 2017
Tardive Dyskinesia (TD) Treatment Market Analysis by Size & Share by 2024
The market for the tardive dyskinesia treatment will grow significantly in the coming years. The key factor that is driving the tardive dyskinesia treatment market is the increasing number of people that are suffering from the neurological disorders. Posted via Industry Today. Follow us on Twitter @…
September 22, 2017
Chronic Lung Diseases Treatment Market to witness steady increase by 2024
The key factor that will fuel the chronic lung diseases treatment market in the future years is the increasing cases of chronic COPD and asthma. Posted via Industry Today. Follow us on Twitter @IndustryToday
September 21, 2017
Chronic Respiratory Diseases Treatment Market: Top Industry Trends & Segments Forecast 2016-2024
The major factors that will contribute to the growth of the chronic respiratory diseases treatment market in the coming years are the favorable initiatives taken by the government, good reimbursement policies, increasing number of cases, and the rise in the number of people addicted to smoking. Pos…
September 21, 2017
Blood Preparation Market will achieve 4.4% growth to surpass USD 64.3 billion by 2024
Key industry players in Blood Preparation Market are focusing on R&D to develop cost effective novel technologies to consolidate their market position. Posted via Industry Today. Follow us on Twitter @IndustryToday
September 21, 2017
Genome Editing Market will grow at 14% CAGR to exceed $7.5 billion by 2024
U.S. Genome Editing Market share was USD 518.5 million in 2015 and will continue to grow at healthy CAGR in coming years, due to the robust growth trend manifested by pharmaceutical industries & adoption of advanced technologies like CRISPR to treat chronic hereditary disorders. Posted via Indu…
September 19, 2017
Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag
Big Pharma expanded in emerging markets 6.1% last quarter, the biggest jump in more than two years, but GlaxoSmithKline and Eli Lilly didn't reap as much growth as their peers—and all of them may face rising threats ahead.